HOME » News & Media

    Vyome advancing first-in-class acne drug with $22M financing

     

    Jan. 23, 2019 (BioWorld) -- Vyome Therapeutics, which specializes in medicines for treating skin diseases caused by resistant microbes, has announced a $22 million financing for the phase IIb trial of its lead molecule, VB-1953, for treatment of moderate to severe acne.


    Source: www.bioworld.com

    Visit: www.vyome.in
    Copyright © 2021 Vyome Biosciences Private Limited.

    Copyright © 2015 Vyome Therapeutics Inc. All rights reserved.